CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on developing chimeric endocytic receptor T-cell (CER-T) therapies for hematologic cancers. The company became publicly traded in early 2024 through a business combination with Phoenix Biotech Acquisition Corp (PBAX), a blank-check vehicle that completed its IPO in 2021 and was sponsored by Phoenix Biotech Sponsor LLC. Operating in the oncology and cell therapy sector, CERO filed a 10-K/A amendment with the SEC on April 30, 2026, covering its most recent fiscal year as a post-merger public entity. For comprehensive data on CERO's SPAC merger history, filing timeline, and post-combination performance, sign up for full access on SpacDesk.